Materialise (MTLS) Q1 2026 Earnings Transcript

Materialise reported Q1 revenue of EUR 66.3 million, flat year over year despite FX headwinds, while adjusted EBITDA rose more than 30% to EUR 8 million and free cash flow reached EUR 5.7 million. Medical revenue increased 7% to EUR 33.2 million, helping offset an 8% decline in Manufacturing, and management reaffirmed full-year 2026 guidance of EUR 273 million-EUR 283 million revenue and EUR 10 million-EUR 12 million adjusted EBIT. The company also announced transfers of RapidFit and eyewear businesses to management teams, launched new medical products, and highlighted sustainability progress with over 1,500 tons of CO2 reductions.

Analysis

The core signal is not the headline revenue stability; it is that the business is increasingly behaving like a hybrid of a software annuity and a cash-generative medical device platform while deliberately shedding lower-quality manufacturing exposure. That mix matters because it should compress the perceived cyclicality discount over the next 2-3 quarters: recurring software, higher medical mix, and management-owned carveouts all point to a cleaner earnings profile that the market can rerate if execution holds.

Second-order, the HP integration is more important for brand reach than near-term revenue. Bundling Magics Print into a sub-$60k system creates a distribution wedge into smaller factories that typically lack enterprise AM software stacks; that broadens the funnel for later upsells into CO-AM and maintenance, but the financial payoff is likely 2027+ rather than this year. In other words, the equity may be underpricing the strategic value of making the software layer the default operating system for a larger installed base.

The main risk is that the market extrapolates the Q1 margin expansion too far. FX was a tailwind/drag mix that can reverse quickly, and the medical margin base still has seasonality plus competitive pressure in certain pockets, so the next catalyst is less about beats and more about whether H2 constant-currency growth and manufacturing profitability show through. If aerospace/defense stays firm while European auto remains weak, the portfolio tilt away from cyclical manufacturing should support guidance, but any slowdown in U.S. healthcare spending or delayed software conversions would expose the current multiple as optimistic.

Contrarian view: the divestments are being read as disciplined capital allocation, but they also reduce embedded optionality in manufacturing just as that segment is inflecting sequentially. If the market gives credit for a cleaner story while ignoring the lost revenue base, the stock could rerate before the cost savings fully show up; if not, the more attractive trade may be to own the cleaner software/medtech exposure and fade the remaining manufacturing drag. HPQ is the clearest external beneficiary from the partnership angle, but MTLS retains the higher operating leverage if the software attach rate improves.

Key Decisions for Investors

• Long MTLS on weakness over the next 2-6 weeks if post-earnings drift persists; thesis is rerating from a de-risked portfolio and improving mix. Risk/reward: 15-20% upside if constant-currency momentum and software onboarding convert, versus downside if FX or guidance confidence deteriorates.
• Pair trade: long MTLS / short a small-cap industrial cyclicals basket or European auto-sensitive names over 1-3 months. The trade expresses relative insulation from European manufacturing softness and captures the margin mix shift. Cover if manufacturing turns positive sooner than expected and cyclicals rebound.
• Buy HPQ as a secondary beneficiary on any pullback over the next quarter; the bundling strategy lowers software adoption friction and deepens ecosystem lock-in. Risk/reward is moderate because monetization is longer-dated, but the setup improves HPQ’s AM narrative with limited near-term downside.
• For tactical traders: sell out-of-the-money MTLS puts 1-2 expiries out if implied vol stays elevated after the call. The balance sheet and guide reaffirmation provide a cushion, while the main risk is a macro FX shock rather than business deterioration.
• If already long MTLS, hedge with a short EUR/USD proxy or reduce ahead of mid-June software availability; the next leg depends on whether constant-currency growth starts to show up in reported numbers.